| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Investigation |
1 Department of Nuclear Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; and 2 Division of Endocrinology, Medicine Department, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
Correspondence: For correspondence or reprints contact: Christian Cohade, Department of Nuclear Medicine, Centre Hospitalier de l'Université de Montréal, 3840 St-Urbain, Montréal, Quebec, Canada, H2W 1T8. E-mail: ccohade2000{at}yahoo.com
The aims of this study were to evaluate the effectiveness of a standardized insulin protocol in reducing glycemia, review 18F-FDG biodistribution with such a protocol, and assess its clinical impact. Methods: Sixty-three patients with glycemia greater than 10 mmol/L received insulin doses intravenously according to a standardized protocol. One hundred six consecutive euglycemic patients (<6.2 mmol/L) served as controls. 18F-FDG biodistribution was evaluated by 2 experienced PET readers on a 5-point visual scale based on muscular uptake. The 63 patients who received insulin were divided into insulin subgroup A, with adequate biodistribution (score 0, 1, or 2) and insulin subgroup B, with altered biodistribution (score 3 or 4). 18F-FDG biodistribution was also evaluated semiquantitatively by standardized uptake value (SUV) measurements over the liver, gluteal muscles, and myocardium. Clinical impact (complications and diagnostic accuracy) was assessed by follow-up. Results: Glycemia decreased from 13 ± 2 to 7 ± 2 mmol/L after insulin injection. Images showed significantly more muscular uptake in patients who received insulin than in the control group (scores 1.6 ± 1.5 vs. 0.4 ± 0.6, P < 0.05). Twenty-five percent of insulin patients studied had altered biodistribution (insulin subgroup B). The two most important factors increasing muscular uptake were the time interval between insulin and 18F-FDG injection (mean in insulin subgroup A, 80.2 ± 17 min; mean in insulin subgroup B, 65.7 ± 10 min; P < 0.01) and the glycemia interval decrease after insulin injection (mean in insulin subgroup A, 5.3 ± 2.6 mmol/L; mean in insulin subgroup B, 7.6 ± 1.8 mmol/L; P < 0.01). In insulin subgroup B, mean hepatic SUV was lower (1.3 ± 0.4 vs. 2.1 ± 0.4, P < 0.01) and mean muscular SUV was higher (1.8 ± 0.1 vs. 0.9 ± 0.01, P < 0.01). Of the 63 patients who received insulin, 6 had hypoglycemia, but only 2 were symptomatic. No patient had severe complications causing permanent disability. Conclusion: A standardized protocol of intravenous insulin before 18F-FDG injection in diabetic cancer patients was safe and effective in reducing glycemia. Acceptable 18F-FDG biodistribution was obtained in 75% of patients receiving insulin. In addition to visually increased muscular uptake, low hepatic 18F-FDG uptake was a good indicator of altered biodistribution.
Key Words: diabetes • insulin • hyperglycemia • FDG • PET • endocrinology • oncology
COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  F.-N. Roy, S. Beaulieu, L. Boucher, I. Bourdeau, and C. Cohade Reply: The Twilight Saga of Insulin Administration in Hyperglycemic Patients Undergoing 18F-FDG PET J. Nucl. Med., March 1, 2010; 51(3): 498 - 498. [Full Text] [PDF]
|
|
|
|
|
|
Y.-F. Lin, F.-C. Yu, and J.-S. Chiu The Twilight Saga of Insulin Administration in Hyperglycemic Patients Undergoing 18F-FDG PET J. Nucl. Med., March 1, 2010; 51(3): 497 - 497. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
